SLC5A2 and chronic kidney disease: Although, not the focus of our review, of great importance is the extensive renal protective benefits that were shown in the listed trials above. SGLT2 inhibitors were shown to decrease albuminuria and the progression of CKD in diabetics with nephropathy, in addition to decreasing the renal composite outcome of end-stage kidney disease (ESKD), doubling of serum creatinine, and renal or CV death in the CREDENCE trial.